



(86) Date de dépôt PCT/PCT Filing Date: 1995/05/26
(87) Date publication PCT/PCT Publication Date: 1995/12/07
(45) Date de délivrance/Issue Date: 2007/02/20
(85) Entrée phase nationale/National Entry: 1996/12/17
(86) N° demande PCT/PCT Application No.: US 1995/006739
(87) N° publication PCT/PCT Publication No.: 1995/032733
(30) Priorité/Priority: 1994/05/27 (US250,445)

(51) Cl.Int./Int.Cl. *C12N 15/86* (2006.01),
A61K 39/12 (2006.01), *A61K 39/193* (2006.01),
C07K 14/155 (2006.01), *C07K 14/165* (2006.01),
C07K 14/18 (2006.01), *C07K 14/285* (2006.01),
C12N 15/40 (2006.01), *C12N 7/01* (2006.01),
C12N 7/04 (2006.01), *A61K 39/00* (2006.01)


(72) Inventeurs/Inventors:
JOHNSTON, ROBERT E., US;
DAVIS, NANCY L., US;
SMITH, JONATHAN F., US;
GRIEDER, FRANZISKA B., US

(73) Propriétaire/Owner:
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,
US

(54) Titre : PROCEDE D'INDUCTION DE REACTION IMMUNITAIRE AU MOYEN D'UN VIRUS VIVANT DE
L'ENCEPHALITE EQUINE DE VENEZUELA EXPRIMANT UN IMMUNOGENE HETEROLOGUE
(54) Title: METHOD OF INDUCING AN IMMUNE RESPONSE WITH A LIVE VENEZUELAN EQUINE ENCEPHALITIS
VIRUS EXPRESSING A HETEROLOGOUS IMMUNOGEN

(57) **Abrégé/Abstract:**

A method of protecting a subject against a disease comprises administering a recombinant Venezuelan Equine Encephalitis (VEE) virus to the subject in an effective immunogenic amount, with the VEE virus containing a heterologous DNA segment, and with the heterologous DNA segment comprising a promoter operable in the subject operatively associated with a DNA encoding an immunogenic protein or peptide effective for protecting the subject from the disease. Preferred promoters are VEE 26S subgenomic promoters, and preferred immunogens are viral immunogens. Novel attenuating mutations useful in carrying out the invention are also disclosed.



(74) **Agent:** SIM & MCBURNEY

Abstract

A method of protecting a subject against a disease comprises administering a recombinant Venezuelan Equine Encephalitis (VEE) virus to the subject in an effective immunogenic amount, with the VEE virus containing a heterologous DNA segment, and with the heterologous DNA segment comprising a promoter operable in the subject operatively associated with a DNA encoding an immunogenic protein or peptide effective for protecting the subject from the disease. Preferred promoters are VEE 26S subgenomic promoters, and preferred immunogens are viral immunogens. Novel attenuating mutations useful in carrying out the invention are also disclosed.

2193210

**METHOD OF INDUCING AN IMMUNE RESPONSE WITH A
LIVE VENEZUELAN EQUINE ENCEPHALITIS VIRUS
EXPRESSING A HETEROLOGOUS IMMUNOGEN**

Field of the Invention

The present invention relates to live attenuated vaccines in general, and particularly relates to attenuated vaccine produced from Venezuelan Equine
5 Encephalitis (VEE) virus.

Background of the Invention

Live, attenuated viral vaccines are among the most successful means of controlling viral disease. However, for some virus pathogens, immunization with a
10 live virus strain may be either impractical or unsafe. One alternative strategy is the insertion of genes encoding immunizing antigens of such agents into the vaccine strain of another virus. However, relatively few such systems are currently available.

15 Hahn et al., *Proc. Natl. Acad. Sci. USA* **89**, 2679 (1992), describes Sindbis virus constructs which express a truncated form of the influenza hemagglutinin protein. The constructs are used to study antigen processing and presentation in vitro and in mice.
20 Although no infectious challenge dose is tested, it is also suggested that such constructs might be used to produce protective B- and T-cell mediated immunity. The final paragraph of the discussion section states:

2193210 PCT/US 95/06739
06 Rec'd PCT/PTO 19 APR 1996

-2-

Although SIN is not likely to be approved for use as a human vaccine, a parallel approach to the one used here for SIN may be applicable for developing live-attenuated vaccine strains using viruses with similar replication strategies, such as attenuated strains of Venezuelan equine encephalitis virus.... (citing Davis et al.)" Insofar as applicant is aware, a problem with the Sindbis vector is that the heterologous insert is unstable therein and is "kicked out" of the vector, with the practical limit for stable inserts being about 1 kb.

Davis et al., U.S. Patent No. 5,185,440, describes cDNAs encoding the VEE virus and attenuated mutations which may be incorporated therein for use in making a vaccine. The use of a subgenomic expression system is neither suggested nor disclosed.

Summary of the Invention

A first aspect of the present invention is a method of protecting a subject against a disease. The method comprises administering a recombinant Venezuelan Equine Encephalitis (VEE) virus to the subject in an effective immunogenic amount, with the VEE virus containing at least one attenuating mutation (and typically two or even three different attenuating mutations), and with the VEE virus containing a heterologous RNA segment. The heterologous RNA segment comprises a promoter operable in the subject operatively associated with a RNA encoding an immunogenic protein or peptide effective for protecting the subject from the disease. The heterologous insert may, optionally, itself serve as an attenuating mutation.

In one preferred embodiment, the heterologous RNA segment of the VEE virus is derived from the genome of a pathogenic organism. According to this embodiment, the heterologous RNA segment comprising the promoter operatively associated with the RNA encoding the immunogenic protein or peptide is effective for

AMENDED SHEET

-3-

protecting the subject from the disease caused by the pathogenic organism.

A second aspect of the present invention is a DNA comprising a cDNA clone coding for an infectious
5 Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a heterologous promoter positioned upstream from the cDNA clone and operatively associated therewith, and further comprising at least one attenuating mutation selected from the group consisting of codons at E1 amino
10 acid 272 which specify an attenuating mutation; codons at E1 amino acid 81 which specify an attenuating mutation; and codons at E1 amino acid 253 which specify an attenuating mutation.

A third aspect of the present invention is a
15 DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a heterologous promoter positioned upstream from the cDNA clone and operatively associated therewith, and further comprising: (a) a first attenuating mutation
20 which is a codon at E1 amino acid 253 which specifies an attenuating mutation; and (b) a second attenuating mutation which is an inactivated E3 amino acid 56 to 59 cleavage recognition site.

A further aspect of the present invention is a
25 recombinant Venezuelan Equine Encephalitis (VEE) virus, the VEE virus comprising at least one attenuating mutation and a heterologous RNA segment encoding an immunogenic protein or peptide, the heterologous RNA segment operatively associated with a promoter, for use
30 as a medicament.

A further aspect of the present invention is a DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript

-3a-

and a first promoter positioned upstream from the cDNA clone and operatively associated therewith, the cDNA clone comprising at least one attenuating mutation and encoding a second promoter operatively associated with a
5 heterologous RNA segment encoding an immunogenic protein or peptide.

A further aspect of the present invention is an infectious VEE virus RNA transcript encoded by the cDNA clone described above.

10 A further aspect of the invention is infectious VEE virus particles containing the RNA transcript described above.

A further aspect of the present invention is a pharmaceutical formulation comprising infectious VEE
15 virus particles as described above in an effective immunogenic amount and a pharmaceutically acceptable carrier.

A further aspect of the invention is use of a recombinant Venezuelan Equine Encephalitis (VEE) virus,
20 in an effective immunogenic amount, wherein the VEE virus comprises at least one attenuating mutation and comprises a heterologous RNA segment, for protecting a subject against a disease, wherein the heterologous RNA segment encodes an immunogenic protein or peptide effective for
25 protecting the subject from the disease and the heterologous RNA segment is operatively associated with a promoter operable in the subject.

Further aspects of the present invention include an infectious VEE virus RNA transcript encoded by
30 cDNA clones as given herein; infectious VEE virus particles containing such RNA transcripts; and

-3b-

pharmaceutical formulations comprising such infectious VEE virus particles, as described above in an effective immunogenic amount, in a pharmaceutically acceptable carrier.

- 5 Frolov et al., Proceedings IXth *International Congress of Virology, Glasgow, Scotland, August 8-13, 1993*, pg. 67, discusses recombinant VEE viruses which express a Hepatitis B virus antigenic protein. The use of an attenuated VEE virus, strain 230, is described.
- 10 However, it is not suggested that the attenuated virus itself be administered to humans. To the contrary, these

2193210

-4-

viruses are used to manufacture the antigenic Hepatitis B virus proteins themselves in tissue culture, which are then harvested and administered to humans. Strain 230 itself replicates poorly, if at all, in humans.

5 The foregoing and other objects and aspects of the present invention are explained in detail in the specification set forth below.

Brief Description of the Drawings

10 **Figure 1** is an illustration of the structure of the shuttle vector containing the structural genes of VEE with three attenuating mutations in the E2 gene, and a second 26S promoter and multiple cloning site inserted directly downstream from the C-terminus of E1, in the 3.2 kb pUC118 plasmid.

15 **Figures 2a-2c** illustrate double promoter vectors.

20 **Figure 3** is a Northern blot analysis of total intracellular RNA from baby hamster kidney (BHK) cells infected with an attenuated VEE mutant, with the mutant containing an HA gene inserted downstream of a second subgenomic promoter, or with the mutant containing an inserted HA gene in a non-coding orientation.

25 **Figures 4a-4d** illustrate the immunocytochemical staining of VEE vector-infected BHK cell monolayers. Cells were infected with either influenza PR/8/34, VEE vector containing the complete influenza HA gene, VEE vector without insert.

30 **Figures 5a-5c** are graphical illustrations of the clinical signs observed in inoculated mice challenged intranasally with influenza. Mice were inoculated with PBS, VEE vector without insert, or VEE vector with the complete influenza HA gene.

35 **Figure 6** is a graphical illustration of pre-viral challenge anti-flu IgG ELISA titers of serum obtained from inoculated mice. Mice were inoculated with

-5-

PBS, VEE vector without insert, or VEE vector with the complete influenza HA gene.

Figure 7 is a graphical illustration of the titer of viable influenza virus observed in lung tissue of inoculated mice 4 days after challenge with influenza. Mice were inoculated with PBS, VEE vector without insert, or VEE vector with the complete influenza HA gene.

Detailed Description of the Invention

10 Complementary DNA sequences encoding live Venezuelan Equine Encephalitis (VEE) virus and pharmaceutical formulations containing the same are known. See, e.g., N. Davis et al., U.S. Patent No. 5,185,440

15 The phrases "attenuating mutation" and "attenuating amino acid" as used herein mean a nucleotide mutation or an amino acid coded for in view of such mutation which result in a decreased probability of causing disease in its host, (i.e., a loss of virulence),
20 in accordance with standard terminology in the art, (See, e.g., B. Davis et al., *Microbiology*, 132 (3d ed. 1980), whether the mutation be a substitution mutation or an in-frame deletion mutation. The phrase "attenuating mutation" excludes mutations which would be lethal to the
25 virus. Examples of known VEE attenuating mutations include codons at E2 amino acid position 76 which specify an attenuating mutation, codons at E2 amino acid position 209 which specify an attenuating mutation, and codons at E2 amino acid 120 which specify an attenuating mutation
30 (see, e.g., U.S. Patent No. 5,185,440 to N. Davis et al.); a G to C mutation at viral RNA nucleotide 3.

Novel attenuating mutations disclosed herein which may be used to carry out the present invention include codons at E1 amino acid 272 which specify an

-5a-

attenuating mutation (preferably a substitution
mutation,

2193210

-6-

such as a threonine or serine (most preferably threonine)); codons at E1 amino acid 81 which specify an attenuating mutation (preferably a substitution mutation, such as an isoleucine or leucine (most preferably isoleucine)); and codons at E1 amino acid 253 which specify an attenuating mutation (preferably a substitution mutation such as a serine or threonine (most preferably serine)).

A novel pair of attenuating mutations which may be inserted together in a cDNA clone encoding an attenuated VEE virus is (a) a first attenuating mutation which is a codon at E1 amino acid 253 which specifies an attenuating mutation; and (b) a second mutation which is an inactivated E3 amino acid 56 to 59 cleavage recognition site. An advantage of this combination of attenuating mutations is that the inactivated cleavage site, of itself, is lethal to the virus. Thus, if the attenuating mutation at E1 amino acid 253 reverts to the virulent wild-type, the remaining mutation kills the virus. The E3 amino acid 56 to 59 cleavage recognition site may be inactivated by any suitable means: the cleavage recognition site may be deleted, in whole or in part; a substitution mutation may be made therein (e.g., an arginine to aspartic acid substitution mutation at amino acid 59).

Attenuating mutations may be introduced into cDNAs encoding live VEE by any suitable means, such as site-directed mutagenesis (see, e.g., U.S. Patent No. 4,873,192 to Kunkel).

The immunogenic protein or peptide, or "immunogen" may be any immunogen suitable for protecting the subject against a disease, including but not limited to microbial, bacterial, protozoal, parasitic, and viral diseases. For example, the immunogen may be an influenza virus immunogen (e.g., an influenza virus hemagglutinin (HA) surface protein, or an equine influenza virus immunogen), or a lentivirus immunogen (e.g., an equine

2193210

PCT/US 95/06739
06 Rec'd PCT/PTO 18 APR 1996

-7-

infectious anemia virus immunogen, a Human Immunodeficiency Virus (HIV) immunogen, such as an HIV-1 immunogen, or an HIV-2 immunogen). The immunogen may also be a coronavirus immunogen (e.g., a transmissible gastroenteritis virus immunogen for pigs, or an infectious bronchitis virus immunogen for chickens,) or a flavivirus immunogen (e.g., a yellow fever virus immunogen or a Japanese encephalitis virus immunogen). If desired, an advantage of the instant invention is that the heterologous insert containing the DNA encoding the immunogen as given above may be a relatively large insert, at least 1 kilobase in length.

The promoter is preferably a Venezuelan equine encephalitis virus 26S subgenomic promoter. This definition is intended to include derivatives of this promoter such as deletion mutants thereof, so long as activity as a promoter is retained. Subjects which may be administered the live attenuated viruses and vaccine formulations disclosed herein include both human and animal (e.g., horse, donkey, pigs, mouse, hamster, monkey, chicken) subjects.

Vaccine formulations of the present invention comprise an immunogenic amount of a live attenuated virus as disclosed herein in combination with a pharmaceutically acceptable carrier. An "immunogenic amount" is an amount of the attenuated virus sufficient to evoke an immune response, particularly an immune response to the protein or peptide encoded by the heterologous DNA carried by the virus, in the subject to which the virus is administered. An amount of from about 10^1 to 10^5 plaque forming units of the live virus per dose is suitable, depending upon the age and species of the subject being treated. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution.

2193210

-8-

Administration of the live attenuated viruses disclosed herein may be carried out by any suitable means, including both parenteral injection (such as intraperitoneal, subcutaneous, or intramuscular injection), by in ovo injection in birds, and by topical application of the virus (typically carried in the pharmaceutical formulation) to an airway surface. Topical application of the virus to an airway surface can be carried out by intranasal administration (e.g., by use of a dropper, swab, or inhaler which deposits a pharmaceutical formulation intranasally). Topical application of the virus to an airway surface can also be carried out by inhalation administration, such as by creating respirable particles of a pharmaceutical formulation (including both solid particles and liquid particles) containing the virus as an aerosol suspension, and then causing the subject to inhale the respirable particles. Methods and apparatus for administering respirable particles of pharmaceutical formulations are well known, and any conventional technique can be employed. See, e.g., U.S. Patent No. 5,304,125 to D. Leith; U.S. Patent No. 5,299,566 to C. Davis and R. Snyder; U.S. Patent No. 5,290,550 to R. Fisher and W. Metzger; and U.S. Patent No. 5,292,498 to R. Boucher.

The following examples are provided to illustrate the present invention, and should not be construed as limiting thereof.

EXAMPLE 1

Construction of a "Second Promoter" Expression Vector

A full-length cDNA clone derived from the TRD strain of VEE, pV3507, and containing three attenuating mutations in the E2 gene was employed in this study. The mutations occur at E2 76 lys, E2 120 lys and E2 209 lys, as reported in Davis et al., *Virology* 183:20 (1991). The cDNA clone was digested with Tth111I, converted to blunt ends with Klenow fragment of E. coli DNA polymerase, and

2193210

-9-

then digested with EcoRI. The 3.9 kb fragment was isolated and ligated with M12 mp19 RF DNA that had been digested with HindIII, treated with Klenow fragment and then digested with EcoRI. The resulting M13 phage, TE3, contained the structural gene region of pV3507, but not the 26S promoter region. The HindIII site was regenerated in the ligation. Single-stranded DNA from phage was produced following transformation of *E. coli* CJ236 (*dut-ung-*) with TE3 and used in the procedure outlined by Kunkel, *Proc. Natl. Acad. Sci. USA* 82:488 (1985), with a synthetic oligonucleotide designed to give the following insertion (in bold):

3' end of E1 gene - -34/+14 26S promoter-ClaI site - the 5' end of 3' untranslated region
nt11,315-nt11,326 nt11,327-nt11,338

15 AAACATAATTGA/GAGGGGCCCCCTATAACTCTCTACGGCTAACCTGAATGGACTACGACATCG/ATACAGCAGCAA

(SEQ ID NO: 1) The regions flanking the inserted sequence are identified by nucleotide numbers based on the full-length VEE sequence, as identified by Kinney et al., *Virology* 170:19 (1989).

20 The correct insertion was identified initially by screening with ClaI digestion of phage RF DNA, and confirmed by sequencing across the junction between the E1 gene and the 3'-untranslated region on single-stranded phage DNA.

25 Thereafter, the DNA fragment containing the pV3507 structural genes and the inserted second 26S promoter was subcloned into pUC118 using HindIII and EcoRI. The HindIII and EcoRI sites were removed by digestion followed by conversion to blunt ends with Klenow fragment and religation to form the pUC118 second promoter clone.

30 A 1.5 kb SalI-SalI "stuffer" fragment lacking an initiator AUG codon was isolated from the glycoprotein gene region of the TR5000 full-length Sindbis clone (identified by Schoepp et al., *Virology* 193:149 (1993)), and inserted into the SalI site of the Cla12 adaptor

2193210

-10-

plasmid. The Cla12 plasmid containing a multiple cloning site (mcs) flanked by ClaI sites was identified by Hughes et al., *J. Virol.* 61:3004 (1987).

Using ClaI, the multiple cloning site
5 containing the inserted TR5000 sequence was cloned into the unique ClaI site of the pUC118 second promoter clone. Digestion with SalI and self-ligation produced the shuttle vector with the structure shown in **Figure 1**.

Thereafter, a viable full-length VEE second
10 promoter expression vector including three attenuating mutations was prepared. The 3.4 kb AflIII-NotI fragment isolated from the shuttle vector and containing a portion of the viral structural genes, the inserted downstream second promoter and the 3'-untranslated region, was used
15 to replace the homologous AflIII-NotI region of the pV3507 full-length clone. Transformants were screened with ClaI. Plasmids containing a ClaI site were linearized at the unique NotI site and transcribed in vitro with T7 RNA polymerase. Transcripts were quantitated by
20 incorporation of alpha-³²P-labeled UTP. Thereafter, monolayers were transfected with transcripts using cationic liposomes (Lipofectin, BRL) and then overlaid with agarose for assay of plaque formation. The transcripts had specific infectivities comparable to
25 those produced from the virulent pV3000 parent clone, indicating that they were fully infectious. **Figures 2a-2c** illustrate double promoter vectors. **Figure 2b** is an illustration of pV4002, one of the downstream second promoter expression vectors.

30

EXAMPLE 2

Construction of an Expression Vector Containing the Influenza HA gene

The complete coding sequence of the HA gene from influenza strain PR/8 cloned into the BamHI site of
35 pGem4 was obtained from Dr. Andy Caton at the Wistar Institute. The 1.7 kb BamHI fragment containing the HA

2193210

-11-

sequence was ligated to BamHI digested, dephosphorylated shuttle vector DNA. V4002 DNA was cut with ClaI and dephosphorylated. Thereafter, the ClaI fragment containing the HA sequence was purified from the shuttle
5 vector and ligated to prepare V4002 DNA. Clones containing the HA gene in the multiple cloning site downstream of the second 26S promoter were identified using digestion with HpaI. Clones including both coding (pV4002HA) and noncoding (pV4002AH) orientations were
10 identified. Tests for the specific infectivity of the transcripts from these clones showed that they were as infectious as parental transcripts, but that these HA-containing genomes made smaller plaques on baby hamster kidney (BHK) cell monolayers. From these results, we
15 determined that the VEE expression vector containing the three attenuating mutations in E2 and an inserted 1.7 kb HA gene was still replication competent, but appeared to grow more slowly than the vector without an insert.

EXAMPLE 3

20 Stability Test of HA Containing Vectors During Replication in Tissue Culture

Total RNA from vector-infected cells was analyzed for HA sequence-containing subgenomic RNA transcripts using Northern blots probed with VEE-specific
25 or HA-specific probes as described in Sambrook et al., *Molecular Cloning* pp 7.39-7.52. Purified cytoplasmic RNA was glyoxylated, electrophoresed on agarose gels containing 0.01 M sodium phosphate (pH 7), and transferred to Biotrans nylon membranes (ICN) with 7.5 M
30 sodium hydroxide. A VEE-specific ³²P-labeled riboprobe was made using a subclone of the VEE glycoprotein gene region (nt 9493 to 10486) in the pGEM3 transcription vector, pGEM19. The pGEM4 HA clone obtained from Dr. Andy Caton at the Wistar Institute was used to generate
35 an HA-specific ³²P-labeled riboprobe. (The HA clone used contained a single nucleotide deletion which resulted in

2193210

-12-

translation of a truncated protein. This mutation affected our ability to detect any expression of protein from this vector, although subgenomic HA-containing viral RNAs were detected.) Duplicate membranes were hybridized to either probe, dried and exposed to x-ray film. The results are illustrated in **Figure 3**. Lanes A and D contain total cytoplasmic RNA from cells infected with a VEE strain containing three attenuating mutations in E2. Lanes B and E contain total cytoplasmic RNA from cells infected with the same mutant strain with a second subgenomic promoter followed by the influenza HA gene in the coding orientation (V4002HA). Lanes C and F contain total cytoplasmic RNA from cells infected with the VEE vector containing the HA gene in the noncoding orientation (V4002AH). Lanes A, B and C were probed with a ³²P-labeled riboprobe complementary to a portion of the influenza HA gene. Lanes D, E and F were probed with a ³²P-labeled riboprobe complementary to a portion of the VEE glycoprotein genes. The positions of ribosomal RNA markers were determined in a parallel lane stained with ethidium bromide. VEE genome length RNA (40S) was not detectable in this experiment.

The results indicate that deletion mutants of both the V4002HA and V4002AH vectors were arising during replication in tissue culture. However, some subgenomic RNAs in V4002HA-infected cells still contained HA sequences, and a significant fraction of these were of a size to accommodate the complete HA gene. The results revealed some instability of the inserted sequence.

2193210

-13-

EXAMPLE 4

Expression in Cultured BHK cells of Influenza PR/8 HA
Gene from a Downstream Promoter Expression Vector
with Two Attenuating Mutations

5 The complete coding sequence of the HA gene
from influenza PR/8 cloned into the HindIII site of
pBR322 was obtained from Dr. P. Palese at the Mt. Sinai
School of Medicine. The HA-containing HindIII fragment
was ligated to the HindIII-cut and dephosphorylated
10 shuttle vector (see **Figure 1**). ClaI was then used to
insert these HA sequences in both coding (V4036a) and
noncoding (V4036e) orientations into a VEE second
promoter expression vector that carried two attenuating
mutations, E2 lys 209 and E1 thr 272. RNA transcribed in
15 vitro from these clones showed comparable specific
infectivities to RNA from the parental clone without the
HA gene. Virus-containing supernatants obtained
following transfection of BHK cells with cationic
liposomes contained both small and large plaques, with
20 the proportion of large plaques increasing with time. A
greater proportion of large plaque variants were seen
with V4036a, carrying HA in the coding orientation, than
with V4036e.

BHK cell monolayers were infected at a
25 multiplicity of 1 with either egg-grown influenza virus
(PR/8 strain), the second promoter expression vector with
the HA gene in the coding orientation, or the vector
without the insert. At 6 hr post-infection, the
monolayers were fixed with methanol:acetone (1:1) at
30 20 °C and air dried. Using the horseradish peroxidase,
biotin-avidin detection system (Vector labs), cells were
tested for the presence of viral antigens using an HA-
specific monoclonal antibody, or VEE-specific hyperimmune
mouse ascites fluid, as primary antibodies. Cells were
35 then counterstained with Meyer's hematoxylin. The
monolayers infected with influenza PR/8 or with the
coding HA vector showed positive staining for HA. The

2193210

-14-

results are illustrated in **Figures 4a-4d**. **Figure 4a** illustrates cells infected with influenza PR/8 stained with anti-HA antibody. **Figure 4b** illustrates VEE HA-vector infected cells stained with anti-HA antibody. **Figure 4c** illustrates cells infected with VEE vector without insert stained with anti-VEE antibody. **Figure 4d** illustrates cells infected with VEE vector without insert stained with anti-HA antibody.

The HA stain in HA vector infected cells was cytoplasmic, and was as intense, under these conditions, as the staining for HA in the influenza-infected control monolayers. These results indicate that influenza HA can be expressed at normal levels from the second 26S promoter in a form that is detectable by this anti-HA monoclonal antibody, and that an infectious VEE virus carrying the inserted gene can be produced.

EXAMPLE 5

Protection of Mice Against Influenza Challenge

Four-week-old CD-1 mice were inoculated subcutaneously into each rear footpad with 1×10^4 pfu of (1) diluent (PBS) alone, (2) the HA-expressing doubly attenuated vector (V4036a), or with (3) the vaccine vector without insert. Three weeks later, the mice were challenged intranasally with 10^5 EID₅₀ (50% egg infectious dose) of influenza virus. The results are reported in **Figures 5a-5c**. All 24 control mice suffered severe disease and 50% died. Only one of 12 HA-vector-inoculated mice died, and another exhibited signs of disease for one day and recovered.

Pre-challenge anti-flu serum IgG ELISA titers were measured, and the results are illustrated in **Figure 6**. The geometric mean ELISA titer of anti-HA serum IgG in the HA-vector inoculated mice was 246, while sera from only 3 of 24 control mice gave a detectable titer, and they were positive only at the lowest dilution tested (1:50). The two HA-vector-inoculated mice affected by

2193210

-15-

the influenza challenge showed no detectable anti-HA IgG. Therefore, in 10 of 12 mice, the HA-vector elicited a detectable level of anti-HA serum IgG, and 11 of 12 mice were protected against lethal influenza challenge.

5

EXAMPLE 6**Protection of Mice Against Influenza Challenge**

Four-week-old CD-1 mice were inoculated subcutaneously into each rear footpad with 1×10^4 pfu of (1) diluent (PBS) alone, (2) the HA-expressing doubly
10 attenuated vector, or with (3) the vaccine vector without insert. Three weeks later, the mice were challenged intranasally with 10^5 EID₅₀ (50% egg infectious dose) of influenza virus. The lungs were removed 4 days after challenge. Lung tissue was homogenized in PBS + 0.1% BSA
15 to give a 20% suspension, centrifuged, aliquoted and frozen at -70°C . For each animal, two aliquots were assayed for pfu on MDCK cells under agarose containing 0.1% trypsin. No influenza infectivity was detected in the lungs of mice previously immunized with the HA-vector
20 at a detection level of 1.25×10^2 pfu/gm tissue (25 pfu/average lung). The geometric mean titers (represented by solid dots) calculated for the animals in the control groups with measurable virus titers, were 3.04×10^6 pfu/gm for PBS-inoculated mice, and 1.93×10^6
25 pfu/gm for mice inoculated with VEE vector alone. The results are reported in **Figure 7**. The results suggest a very low level of challenge virus replication in the vaccinated animals.

The foregoing is illustrative of the present
30 invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

2193210

-16-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Johnston, Robert E.
Davis, Nancy L.
Smith, Jonathon F.
Grieder, Franziska B.

(ii) TITLE OF INVENTION: METHOD OF INDUCING AN IMMUNE RESPONSE
WITH A LIVE VENEZUELAN EQUINE ENCEPHALITIS VIRUS
EXPRESSING A HETEROLOGOUS IMMUNOGEN

(iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Kenneth D. Sibley
(B) STREET: Post Office Drawer 34009
(C) CITY: Charlotte
(D) STATE: North Carolina
(E) COUNTRY: USA
(F) ZIP: 28234

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/250,445
(B) FILING DATE: 27-MAY-1994
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Sibley, Kenneth D.
(B) REGISTRATION NUMBER: 31,665
(C) REFERENCE/DOCKET NUMBER: 5470-79

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (919) 420-2200
(B) TELEFAX: (919) 881-3175

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 74 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

2193210

-17-

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAACATAATT GAGAGGGGCC CCTATAACTC TCTACGGCTA ACCTGAATGG ACTACGACAT 60

CGATACAGCA GCAA. 74

-18-

WE CLAIM:

1. A recombinant Venezuelan Equine Encephalitis (VEE) virus, said VEE virus comprising at least one attenuating mutation and a heterologous RNA segment encoding an immunogenic protein or peptide, said heterologous RNA segment operatively associated with a promoter, for use as a medicament.
5
2. The recombinant VEE virus according to claim 1, comprising at least one attenuating mutation selected from the group consisting of:
10
 - (i) a G to C mutation at viral RNA nucleotide 3;
 - (ii) an attenuating mutation in the E1 region;
 - 15 and
 - (iii) an attenuating mutation in the E2 region.
3. The recombinant VEE virus according to claim 2 comprising at least one attenuating mutation in the E1 region selected from the group consisting of:
20
 - (i) codons at E1 amino acid 272 which specify an attenuating mutation;
 - (ii) codons at E1 amino acid 81 which specify an attenuating mutation; and
 - 25 (iii) codons at E1 amino acid 253 which specify an attenuating mutation.
4. A recombinant VEE virus according to claim 2 or claim 3 comprising at least one attenuating mutation in the E2 region selected from the group consisting of:
30
 - (i) codons at E2 amino acid position 76 which specify an attenuating mutation;

-19-

- (ii) codons at E2 amino acid position 209 which specify an attenuating mutation; and
- (iii) codons at E2 amino acid position 120 which specify an attenuating mutation.

5

5. The recombinant VEE virus according to any one of claims 1 to 4, for use in protecting against a viral disease.

10

6. The recombinant VEE virus according to any one of claims 1 to 5, wherein said immunogenic protein or peptide is selected from the group consisting of influenza immunogens, lentivirus immunogens, coronavirus immunogens, and flavivirus immunogens.

15

7. The recombinant VEE virus according to claim 6, wherein said immunogenic protein or peptide is an influenza immunogen.

20

8. The recombinant VEE virus according to claim 7, wherein said immunogenic protein or peptide is an influenza virus hemagglutinin (HA) surface protein.

9. The recombinant VEE virus according to claim 6, wherein said immunogenic protein or peptide is a lentivirus immunogen.

10. The recombinant VEE virus according to claim 9, wherein said immunogenic protein or peptide is an equine infectious anemia virus immunogen.

30

-20-

11. The recombinant VEE virus according to claim 6, wherein said immunogenic protein or peptide is a coronavirus immunogen.

5 12. The recombinant VEE virus according to claim 6, wherein said immunogenic protein or peptide is a flavivirus immunogen.

10 13. The recombinant VEE virus according to any one of claims 1 to 12, wherein said heterologous RNA segment is at least 1 kilobase in length.

15 14. The recombinant VEE virus according to any one of claims 1 to 13, wherein said promoter is a VEE virus 26S promoter.

20 15. The VEE virus according to any one of claims 1 to 14, wherein said medicament is administrable parenterally.

 16. The VEE virus according to any one of claims 1 to 14, wherein said medicament is administrable by topically applying said virus to an airway surface.

25 17. The VEE virus according to any one of claims 1-14, wherein said medicament is administrable intranasally.

30 18. The VEE virus according to any one of claims 1-14, wherein said medicament is administrable by inhalation.

-21-

19. A DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a first promoter positioned upstream from said cDNA clone and operatively associated therewith, said cDNA clone comprising at least one attenuating mutation and encoding a second promoter operatively associated with a heterologous RNA segment encoding an immunogenic protein or peptide.

20. The DNA according to claim 19, comprising at least one attenuating mutation selected from the group consisting of:

- (i) a G to C mutation at viral RNA nucleotide 3;
- (ii) an attenuating mutation in the E1 region; and
- (iii) an attenuating mutation in the E2 region.

21. The DNA according to claim 20, comprising at least one attenuating mutation in the E1 region selected from the group consisting of:

- (i) codons at E1 amino acid 272 which specify an attenuating mutation;
- (ii) codons at E1 amino acid 81 which specify an attenuating mutation; and
- (iii) codons at E1 amino acid 253 which specify an attenuating mutation.

22. The DNA according to claim 20 or claim 21, comprising at least one attenuating mutation in the E2 region selected from the group consisting of:

- (i) codons at E2 amino acid position 76 which specify an attenuating mutation;

-22-

- (ii) codons at E2 amino acid position 209 which specify an attenuating mutation; and
- (iii) codons at E2 amino acid position 120 which specify an attenuating mutation.

5

23. The DNA according to claim 19, said at least one attenuating mutation comprising:

a first attenuating mutation which is a codon at E1 amino acid 253 which specifies an attenuating
10 mutation; and

a second attenuating mutation which is an inactivated E3 amino acid 56 to 59 cleavage recognition site.

15

24. The DNA according to claim 23, wherein said E3 amino acid 56 to 59 cleavage recognition site is deleted.

25. The DNA according to claim 23, wherein
20 said E3 amino acid 56 to 59 cleavage recognition site contains an inactivating substitution mutation.

26. The DNA according to claim 23, wherein
25 said E3 amino acid 56 to 59 cleavage recognition site contains an arginine to aspartic acid substitution mutation at amino acid 59.

27. The DNA according to any one of claims 19 to 26, wherein said heterologous RNA segment is at least
30 1 kilobase in length.

28. An infectious VEE virus RNA transcript encoded by the cDNA clone of any one of claims 19 to 27.

-23-

29. Infectious VEE virus particles containing the RNA transcript of claim 28.

30. A pharmaceutical formulation comprising
5 infectious VEE virus particles according to claim 29, in an effective immunogenic amount and a pharmaceutically acceptable carrier.

31. Use of a recombinant Venezuelan Equine
10 Encephalitis (VEE) virus, in an effective immunogenic amount, wherein said VEE virus comprises at least one attenuating mutation and comprises a heterologous RNA segment, for protecting a subject against a disease,
wherein said heterologous RNA segment encodes an
15 immunogenic protein or peptide effective for protecting the subject from the disease and said heterologous RNA segment is operatively associated with a promoter operable in said subject.

20 32. The use of claim 31, wherein the VEE virus comprises at least one attenuating mutation selected from the group consisting of:

- (i) a G to C mutation at viral RNA nucleotide 3;
- 25 (ii) an attenuating mutation in the E1 region;
and
- (iii) an attenuating mutation in the E2 region.

33. The use of claim 32, wherein the VEE virus
30 comprises at least one attenuating mutation in the E1 region selected from the group consisting of:

- (i) codons at E1 amino acid 272 which specify an attenuating mutation;

-24-

- (ii) codons at E1 amino acid 81 which specify an attenuating mutation; and
- (iii) codons at E1 amino acid 253 which specify an attenuating mutation.

5

34. The use of claim 32 or 33, wherein the VEE virus comprises at least one attenuating mutation in the E2 region selected from the group consisting of:

- (i) codons at E2 amino acid position 76 which specify an attenuating mutation;
- (ii) codons at E2 amino acid position 209 which specify an attenuating mutation; and
- (iii) codons at E2 amino acid position 120 which specify an attenuating mutation.

10
15

35. The use of any one of claims 31 to 34, wherein the disease is a viral disease.

36. The use of any one of claims 31 to 34, wherein said immunogenic protein or peptide is selected from the group consisting of influenza immunogens, lentivirus immunogens, coronavirus immunogens, and flavivirus immunogens.

25 37. The use of claim 36, wherein said immunogenic protein or peptide is an influenza immunogen.

38. The use of claim 37, wherein said immunogenic protein or peptide is an influenza virus hemagglutinin (HA) surface protein.

39. The use of claim 38, wherein said immunogenic protein or peptide is a lentivirus immunogen.

-25-

40. The use of claim 39, wherein said immunogenic protein or peptide is an equine infectious anemia virus immunogen.

5 41. The use of claim 36, wherein said immunogenic protein or peptide is a coronavirus immunogen.

10 42. The use of claim 36, wherein said immunogenic protein or peptide is a flavivirus immunogen.

15 43. The use of any one of claims 31 to 42, wherein said heterologous RNA segment is at least 1 kilobase in length.

 44. The use of any one of claims 31 to 43, wherein said promoter is a VEE virus 26S promoter.

20 45. The use of any one of claims 31 to 44, wherein said medicament is administrable parenterally.

 46. The use of any one of claims 31 to 44, wherein said medicament is topically administrable to an airway surface.

25 47. The use of any one of claims 31 to 44, wherein said medicament is administrable intranasally.

30 48. The use of any one of claims 31 to 44, wherein said medicament is administrable by inhalation.

 49. The use of claim 31, wherein said at least one attenuating mutation comprises:

-26-

a first attenuating mutation which is a codon
at E1 amino acid 253 which specifies an attenuating
mutation; and

5 a second attenuating mutation which is an
inactivated E3 amino acid 56 to 59 cleavage recognition
site.

10 50. The use of claim 49, wherein said E3 amino
acid 56 to 59 cleavage recognition site is deleted.

51. The use of claim 49, wherein said E3 amino
acid 56 to 59 cleavage recognition site contains an
inactivating substitution mutation.

15 52. The use of claim 49, wherein said E3 amino
acid 56 to 59 cleavage recognition site contains an
arginine to aspartic acid substitution mutation at amino
acid 59.

1/6




FIG. 1.




FIG. 2a.




FIG. 2b.




FIG. 2c.

2193210

2/6




FIG. 3



FIG. 4a




FIG. 4b



FIG. 4c




FIG. 4d

4/6




FIG. 5a.




FIG. 5b.

5/6




FIG. 5c.





FIG. 6.

6/6

FIG. 7.